The priorix market research report is one of a series of new reports that provides priorix market statistics, including priorix industry global market size, regional shares, competitors with a priorix market share, detailed priorix market segments, market trends and opportunities, and any further data you may need to thrive in the priorix industry. This priorix market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can be attributed to rising adoption of WHO recommendations on immunization, rising school-based vaccination, expansion of retail pharmacy-based immunization services, focus on regional manufacturing, and increase in international funding. Major trends in the forecast period include partnerships for vaccine distribution, AI-based surveillance on immunization gaps, a shift towards decentralized vaccine manufacturing, the use of digital tools for vaccination tracking, and the development of temperature-stable vaccine formulation.
The increasing prevalence of mumps is expected to significantly drive the growth of the Priorix market. Mumps is a contagious viral infection that causes painful swelling of the salivary glands, particularly the parotid glands. This rise in cases is largely due to reduced immunity from childhood vaccinations, insufficient vaccine coverage, and the occurrence of outbreaks in environments such as schools and colleges. Priorix helps prevent mumps by offering active immunization against the mumps virus as part of a combination vaccine. It works by stimulating the immune system to produce antibodies, which lowers the risk of infection and helps control outbreaks. For example, in December 2024, the Centers for Disease Control and Prevention reported that the number of mumps cases in the U.S. rose from 386 in 2022 to 436 in 2023. Consequently, the growing prevalence of mumps is driving demand for Priorix.
The growth in healthcare spending is also expected to boost the Priorix market in the coming years. Healthcare expenditure encompasses the financial resources spent on medical services, infrastructure, pharmaceuticals, and healthcare-related activities. This expenditure is on the rise due to factors such as higher operational costs, the increasing prevalence of chronic and lifestyle diseases, advances in medical technology, and improved access to healthcare services. Rising healthcare spending facilitates wider access to vaccination programs, including those for measles, mumps, and rubella, thus supporting the use of Priorix. For example, in May 2024, the UK’s healthcare expenditure grew by 5.6% from 2022 to 2023, a substantial increase compared to the previous year’s growth rate of 0.9%. This increase in spending, particularly in long-term health and social care, contributes to expanding vaccination efforts and drives demand for Priorix.
A key development in the Priorix market is the regulatory approval of the vaccine for preventing measles, mumps, and rubella. This approval provides an additional option for vaccination against these highly contagious diseases, which continue to be major global health threats. In June 2022, GSK announced that the U.S. Food and Drug Administration had approved Priorix as a live vaccine for individuals aged 12 months and older. The vaccine is administered as a two-dose series: the first dose between 12 and 15 months of age and the second between 4 and 6 years old. It can also serve as a second dose for individuals who previously received a first dose of a different MMR vaccine. This approval has expanded the available options for MMR vaccination, supporting its adoption in both routine immunization programs and catch-up schedules.
The key company operating in the priorix market is GSK plc.
North America was the largest region in the priorix market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in priorix report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the priorix market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Priorix is a combination vaccine designed to protect against three infectious diseases: measles, mumps, and rubella (MMR). It contains live, attenuated viruses for each of these diseases, which stimulate the immune system to provide immunity. Typically administered as a subcutaneous or intramuscular injection, Priorix is given in two doses - the first between 12 and 15 months of age, and the second around 4 to 6 years old, depending on national immunization schedules.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main formulations of priorix include lyophilized (freeze-dried) and liquid forms. Lyophilized vaccines are freeze-dried to maintain stability and extend shelf life under controlled conditions. The vaccine targets measles, mumps, and rubella, and is primarily used in infants (0-12 months) and children (1-5 years). It is administered by various end users, including pediatric patients and healthcare providers.
The priorix market consists of sales of pre-filled vials, diluents, and delivery kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to rising adoption of WHO recommendations on immunization, rising school-based vaccination, expansion of retail pharmacy-based immunization services, focus on regional manufacturing, and increase in international funding. Major trends in the forecast period include partnerships for vaccine distribution, AI-based surveillance on immunization gaps, a shift towards decentralized vaccine manufacturing, the use of digital tools for vaccination tracking, and the development of temperature-stable vaccine formulation.
The increasing prevalence of mumps is expected to significantly drive the growth of the Priorix market. Mumps is a contagious viral infection that causes painful swelling of the salivary glands, particularly the parotid glands. This rise in cases is largely due to reduced immunity from childhood vaccinations, insufficient vaccine coverage, and the occurrence of outbreaks in environments such as schools and colleges. Priorix helps prevent mumps by offering active immunization against the mumps virus as part of a combination vaccine. It works by stimulating the immune system to produce antibodies, which lowers the risk of infection and helps control outbreaks. For example, in December 2024, the Centers for Disease Control and Prevention reported that the number of mumps cases in the U.S. rose from 386 in 2022 to 436 in 2023. Consequently, the growing prevalence of mumps is driving demand for Priorix.
The growth in healthcare spending is also expected to boost the Priorix market in the coming years. Healthcare expenditure encompasses the financial resources spent on medical services, infrastructure, pharmaceuticals, and healthcare-related activities. This expenditure is on the rise due to factors such as higher operational costs, the increasing prevalence of chronic and lifestyle diseases, advances in medical technology, and improved access to healthcare services. Rising healthcare spending facilitates wider access to vaccination programs, including those for measles, mumps, and rubella, thus supporting the use of Priorix. For example, in May 2024, the UK’s healthcare expenditure grew by 5.6% from 2022 to 2023, a substantial increase compared to the previous year’s growth rate of 0.9%. This increase in spending, particularly in long-term health and social care, contributes to expanding vaccination efforts and drives demand for Priorix.
A key development in the Priorix market is the regulatory approval of the vaccine for preventing measles, mumps, and rubella. This approval provides an additional option for vaccination against these highly contagious diseases, which continue to be major global health threats. In June 2022, GSK announced that the U.S. Food and Drug Administration had approved Priorix as a live vaccine for individuals aged 12 months and older. The vaccine is administered as a two-dose series: the first dose between 12 and 15 months of age and the second between 4 and 6 years old. It can also serve as a second dose for individuals who previously received a first dose of a different MMR vaccine. This approval has expanded the available options for MMR vaccination, supporting its adoption in both routine immunization programs and catch-up schedules.
The key company operating in the priorix market is GSK plc.
North America was the largest region in the priorix market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in priorix report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the priorix market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Priorix is a combination vaccine designed to protect against three infectious diseases: measles, mumps, and rubella (MMR). It contains live, attenuated viruses for each of these diseases, which stimulate the immune system to provide immunity. Typically administered as a subcutaneous or intramuscular injection, Priorix is given in two doses - the first between 12 and 15 months of age, and the second around 4 to 6 years old, depending on national immunization schedules.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main formulations of priorix include lyophilized (freeze-dried) and liquid forms. Lyophilized vaccines are freeze-dried to maintain stability and extend shelf life under controlled conditions. The vaccine targets measles, mumps, and rubella, and is primarily used in infants (0-12 months) and children (1-5 years). It is administered by various end users, including pediatric patients and healthcare providers.
The priorix market consists of sales of pre-filled vials, diluents, and delivery kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Priorix Market Characteristics4. Priorix Market Trends And Strategies5. Priorix Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Priorix Pricing Analysis & Forecasts30. Global Priorix Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Priorix Market32. Recent Developments In The Priorix Market
3. Priorix Market Biologic Drug Characteristics
6. Global Priorix Growth Analysis And Strategic Analysis Framework
8. Priorix Market Segmentation
9. Global Priorix Epidemiology Of Clinical Indications
10. Priorix Market Regional And Country Analysis
11. Asia-Pacific Priorix Market
12. China Priorix Market
13. India Priorix Market
14. Japan Priorix Market
15. Australia Priorix Market
16. South Korea Priorix Market
17. Western Europe Priorix Market
18. UK Priorix Market
19. Germany Priorix Market
20. France Priorix Market
21. Eastern Europe Priorix Market
22. North America Priorix Market
23. USA Priorix Market
24. Canada Priorix Market
25. South America Priorix Market
26. Middle East Priorix Market
27. Africa Priorix Market
28. Priorix Market Competitive Landscape And Company Profiles
29. Global Priorix Market Pipeline Analysis
33. Priorix Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Priorix Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on priorix market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for priorix ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The priorix market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Formulation: Lyophilized (Freeze-dried); Liquid2) By Indication: Measles; Mumps; Rubella
3) By Age Group: Infants (0-12 months); Children (1-5 years)
4) By End Users: Pediatric Patients; Healthcare Providers
Key Companies Profiled: GSK plc
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- GSK plc
